Enovis(US:ENOV)2025-08-07 12:30Financial Performance - Enovis reported a net sales increase to $565 million in Q2 2025, compared to $525 million in Q2 2024[20] - Adjusted Earnings Per Share (EPS) increased by 27% in Q2 2025[8] - The adjusted gross profit margin improved from 59.6% in Q2 2024 to 60.5% in Q2 2025[20] - Adjusted EBITDA for Q2 2025 was $97 million, compared to $90 million in Q2 2024, maintaining a margin of 17.2%[20] - For the first half of 2025, net sales reached $1.123 billion, up from $1.041 billion in the first half of 2024[20] - Adjusted EPS for the first half of 2025 was $1.60, compared to $1.13 in the first half of 2024[20] Segment Performance - Reconstructive segment sales grew by 11% year-over-year, with 8% organic growth, reaching $274 million in Q2 2025[10] - Prevention & Recovery (P&R) segment sales grew by 5% year-over-year, with 3% organic growth, reaching $291 million in Q2 2025[15] - Extremities within the Reconstructive segment experienced 10% growth[14] Outlook - Enovis raised its full-year 2025 revenue outlook to $2.245-$2.275 billion[22] - The company anticipates organic growth of approximately 6.25-6.75% year-over-year[25]